Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T.
Dispenzieri A, Gertz MA, Saenger A, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Leung N, Zeldenrust S, Hayman SR, Kapoor P, Grogan M, Hwa L, Russell SJ, Go RS, Rajkumar SV, Kyle RA, Jaffe A.
Dispenzieri A, et al. Among authors: leung n.
Am J Hematol. 2015 Jun;90(6):524-8. doi: 10.1002/ajh.24001. Epub 2015 Apr 2.
Am J Hematol. 2015.
PMID: 25753178
Free article.
Clinical Trial.